Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for MASH and cardiometabolic diseases.

Eli Lilly & Co. is tapping the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of ...

It is unclear why an independent data safety monitoring board recommended the suspension of Pliant’s Phase IIb/III BEACON-IPF ...

Resmed has its origins in the 1980s, when Sydney sleep expert Dr Colin Sullivan converted a vacuum cleaner to deal with the ...

Enworth's Lilly Robertson won a pair of Tennessee state swimming titles, Elizabeth Helmer won one of her own and Blake ...

A couple of inches of rain will hit parts of Southern California by Wednesday. KTLA's Kacey Montoya reports on Sunday, Feb. 9 ...

Some of the market’s biggest winners start off as the smallest players. While trillion-dollar tech giants like the ...

The Tennessee high school swimming season concluded with the TISCA championships this weekend. Here are five takeaways from ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

Eli Lilly (LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...